FDA Alert: Infectious Diseases Drug News Roundup 2026

Key Takeaways

• FDA approved Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated UTI caused by E. coli, K. pneumoniae, or P. mirabilis in adult women with limited or no alternative oral options.
• Orlynvah dosing on the label is one tablet orally twice daily for 5 days; it is not indicated for complicated UTI or complicated intra-abdominal infection.
• FDA’s zoliflodacin NDA review materials list a PDUFA goal date of December 15, 2025, with QIDP and Priority Review designations for uncomplicated urogenital gonorrhea.
• Teams should treat “2026 alert roundups” as pointers to labels and NCT pages — not as substitutes for primary FDA text.

What did FDA approve for uncomplicated UTI?

FDA announced approval of Orlynvah oral tablets for uncomplicated urinary tract infection in adult women who have limited or no alternative oral antibacterial treatment options. The labeled pathogens are Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. The product combines sulopenem etzadroxil with probenecid.

Effectiveness was evaluated in two Phase 3 randomized, double-blind trials. Trial 1 (NCT05584657) enrolled 2,214 adult women and compared Orlynvah with amoxicillin/clavulanate; composite response was 62% versus 55% in patients with amoxicillin/clavulanate-susceptible pathogens. Trial 2 (NCT03354598) enrolled 1,660 adult women and compared Orlynvah with ciprofloxacin among ciprofloxacin-resistant pathogens; composite response was 48% versus 33%. Across both trials, 1,932 patients were treated with Orlynvah.

See the FDA Orlynvah approval announcement and the Orlynvah prescribing information on Drugs@FDA.

Why do label limitations matter for BD and medical affairs?

The FDA label states Orlynvah is not indicated for complicated UTI or complicated intra-abdominal infections, and not as step-down after intravenous therapy for those syndromes. That boundary is material for hospital formulary and stewardship narratives that blur uncomplicated cystitis with cUTI.

The application carried Fast Track, Qualified Infectious Disease Product (QIDP), and Priority Review designations. Common adverse reactions (≥2%) listed include diarrhea, nausea, vulvovaginal mycotic infection, headache, and vomiting. Hypersensitivity, Clostridioides difficile–associated diarrhea, and gout exacerbation appear in Warnings and Precautions.

• Dose: one tablet twice daily for 5 days
• Food: administration with food is recommended
• Contraindications include hypersensitivity to components or other beta-lactams, blood dyscrasias, uric acid kidney stones, and concomitant ketorolac

What is the status of zoliflodacin for gonorrhea?

FDA integrated review materials for NDA 219491 describe zoliflodacin as a spiropyrimidinetrione bacterial type II topoisomerase inhibitor for uncomplicated urogenital gonorrhea. The review lists QIDP designation, Priority Review, and a PDUFA goal date of December 15, 2025. Primary evidence cited includes Phase 3 trial STI_Zoli001 and confirmatory Phase 2 work (DMID 14-0014).

Teams tracking infectious-disease pipelines should separate a completed review recommendation from a marketed label until Drugs@FDA shows an approved package insert. For trial context, registry and FDA document references remain the diligence anchors.

Primary document: FDA integrated review for zoliflodacin NDA 219491.

How should investors read “infectious disease alerts” in 2026?

Alert-style content often mixes approvals, CRL risk, trial holds, and safety communications. For antibacterials, the highest-signal public artifacts are FDA news releases, Drugs@FDA labels, and ClinicalTrials.gov NCT records with enrollment and endpoint definitions. Secondary market chatter without those anchors should be discarded.

For Orlynvah, the commercial question is stewardship uptake in outpatient uUTI with limited oral options — not expansion into cUTI without new labeled evidence. For zoliflodacin, the question is whether an oral single-dose gonorrhea option reaches a final approved label and how CDC treatment guidance may evolve afterward.

Data points that clear a screening filter

• Orlynvah uUTI indication limited to three named pathogens in adult women
• NCT05584657: 2,214 women randomized/treated in Trial 1
• NCT03354598: 1,660 women randomized/treated in Trial 2
• Composite response 48% vs 33% versus ciprofloxacin in resistant-pathogen Trial 2
• Zoliflodacin PDUFA goal date listed as December 15, 2025 in FDA review materials

What remains unproven

This roundup does not claim a 2026 novel antibacterial approval calendar beyond what Drugs@FDA and FDA news pages document. It does not assert Orlynvah efficacy in complicated UTI. It does not invent post-approval resistance rates or market share. If a claimed “FDA alert” cannot be matched to an FDA.gov or ClinicalTrials.gov URL, delete it.

Related NovaPharma coverage

• FDA approves OTC Rextovy for opioid overdose
• FDA guidance on sharing potential NDA patent information
• FDA real-time clinical trials AI pilot comment period

Frequently Asked Questions

Primary Sources

1. FDA Orlynvah approval announcement
2. Orlynvah prescribing information (Drugs@FDA)
3. FDA integrated review: zoliflodacin NDA 219491